Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform.
Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief.
The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions.
In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic.
Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 11, 25 | -0.03 Increased by +99.30% | 0.09 Decreased by -133.33% |
| Oct 31, 24 | -0.25 Increased by +44.44% | -0.01 Decreased by -2.40 K% |
| Aug 8, 24 | -0.01 Increased by +94.74% | 0.05 Decreased by -120.00% |
| May 8, 24 | -0.31 Increased by +34.04% | -0.19 Decreased by -63.16% |
| Mar 13, 24 | -4.30 Decreased by -1.16 K% | -0.26 Decreased by -1.55 K% |
| Nov 2, 23 | -0.45 Decreased by -200.00% | -0.37 Decreased by -21.62% |
| Aug 8, 23 | -0.19 Increased by +5.00% | -0.27 Increased by +29.63% |
| May 9, 23 | -0.47 Decreased by -135.00% | -0.30 Decreased by -56.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | -1.29 M Decreased by -103.00% | -21.86 M Increased by +65.29% | Increased by +1.69 K% Increased by +1.26 K% |
| Sep 30, 24 | 38.75 M Decreased by -6.54% | -29.92 M Decreased by -354.96% | Decreased by -77.20% Decreased by -386.80% |
| Jun 30, 24 | 41.92 M Decreased by -5.37% | -88.00 K Increased by +96.79% | Decreased by -0.21% Increased by +96.61% |
| Mar 31, 24 | 40.52 M Increased by +6.85% | -4.51 M Increased by +56.39% | Decreased by -11.14% Increased by +59.18% |
| Dec 31, 23 | 42.97 M Increased by +8.45% | -63.00 M Decreased by -1.18 K% | Decreased by -146.61% Decreased by -1.08 K% |
| Sep 30, 23 | 41.47 M Increased by +2.98% | -6.58 M Decreased by -57.51% | Decreased by -15.86% Decreased by -52.95% |
| Jun 30, 23 | 44.30 M Increased by +11.71% | -2.74 M Increased by +3.59% | Decreased by -6.19% Increased by +13.70% |
| Mar 31, 23 | 37.92 M Increased by +3.35% | -10.35 M Decreased by -252.88% | Decreased by -27.29% Decreased by -241.43% |